AIP
GNOM icon

Ahrens Investment Partners’s Global X Genomics & Biotechnology ETF GNOM Stock Holding History

Ahrens Investment Partners’s Portfolio GNOM Stock Details GNOM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		$2.46K Buy
+50
New +$2.57K ﹤0.01% 862
2022
Q3 		– Sell
-50
Closed -$2K – 461
2022
Q2 		$2K Hold
50
– – ﹤0.01% 869
2022
Q1 		$3K Buy
+50
New +$3.15K ﹤0.01% 909

Other funds holding GNOM

Northwestern Mutual Wealth Management
Northwestern Mutual Wealth Management Milwaukee, Wisconsin $162B AUM 16.35% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.3B AUM 22.13% 1-Year Est. Return
OCM
One Capital Management Westlake Village, California $3.65B AUM 15.32% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
Lido Advisors
Lido Advisors Los Angeles, California $32.7B AUM 19.2% 1-Year Est. Return
PGA
Portland Global Advisors Portland, Maine $938M AUM 13.22% 1-Year Est. Return
PFG
Prosperity Financial Group San Ramon, California $271M AUM 30.27% 1-Year Est. Return
RJFSA
Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
MIG
McGuire Investment Group Wakefield, Rhode Island $885M AUM 47.78% 1-Year Est. Return

Ahrens Investment Partners's GNOM Position: Q1 2023 in Review

Ahrens Investment Partners opened a new position in Global X Genomics & Biotechnology ETF (GNOM) in Q1 2023: 50 shares worth $2.46K. The stake represents ﹤0.01% of the portfolio and ranks #862 among its holdings. This is a return to the name: Ahrens Investment Partners previously reported a position in GNOM as recently as Q2 2022.

Ahrens Investment Partners first reported a position in GNOM in Q1 2022 and has held it in 3 quarters since. The position peaked at $3K in Q1 2022. 63 funds tracked by Wall St. Rank hold GNOM as of Q1 2023.

  • Ahrens Investment Partners held 50 shares of Global X Genomics & Biotechnology ETF worth $2.46K as of Q1 2023.
  • Global X Genomics & Biotechnology ETF was a new Ahrens Investment Partners position in Q1 2023.
  • Global X Genomics & Biotechnology ETF made up ﹤0.01% of Ahrens Investment Partners's portfolio in Q1 2023, its #862 holding.
  • Ahrens Investment Partners first reported a position in Global X Genomics & Biotechnology ETF in Q1 2022 and has held it in 3 quarters since.
  • Ahrens Investment Partners's Global X Genomics & Biotechnology ETF position peaked at $3K in Q1 2022.
  • 63 funds tracked by Wall St. Rank held Global X Genomics & Biotechnology ETF as of Q1 2023.

Based on Ahrens Investment Partners's 13F filing for Q1 2023, filed 24 Apr 2023.